
# The Science of Breast Tissue Management

Breast Implants Surfaces and Immunology

# Breast Implants Surfaces and Immunology

# Available Breast Implants Surfaces in the Market



# Traditional Breast Implants Manufacturing Processes


Primary Process

Achieved in a single step process


Secondary Processes

- Require a second special treatment process after the shell has been manufactured
- Involve the use of some additional material

### Traditional "Smooth" Surfaces are difficult to control



Illustrative image by Establishment Labs




**Figure 3.** The actual resulting texture of smooth implants is shown. During manufacture, silicone creeps down the surface of the mandrel during curing, resulting in a regularly-ridged topography, rather than one that is strictly smooth.

# Traditional "Smooth" surface is not really smooth




S. BARR ET AL




**Figure 4.** Allergan smooth surface implant in scanning electron microscopy at  $592 \times$  magnification with a  $50-\mu$ m scale bar,  $25-\mu$ m fibroblast representation, and an arrow to illustrate the direction of the ridged surface texture. This scanning electron microscopy image illustrates the directional quality that the ridges on the surface of this implant have, which may be attributed to the drying stage of its manufacture. This image also better illustrates the dimensions of these ridges, especially with respect to an average-sized fibroblast.

# Traditional Salt-loss Texture (Secondary Manufacturing Process)




"Salt-loss" texture 3D topography view taken with uSurf Mobile Profilometer. Images Property of Establishment Labs (2017).



Cavities dimensions' measurements of the "salt-loss" macro-texture, at a scale of 1,00 mm and 55x magnification, taken from equator section. Images Property of Establishment Labs (2017).


# Traditional Salt-loss Texture (Secondary Manufacturing Process)

- "Pitted with cuboid shaped wells" with many irregularities (Barr, Hill and Bayat, 2009).
- Silicon debris.
- Structures outside cellular dimensions.
- Promote Tissue Ingrowth.




Silicone Debris in a cavity of the "salt-loss" macro-texture, at a scale of 100 um and 300x magnification, taken from equator section. Images Property of Establishment Labs (2017).

# Traditional Polyurethane Foam Imprint Texture (Secondary Manufacturing Process)




"PU foam imprint" texture 3D topography view taken with uSurf Mobile Profilometer.



"Negative imprint with foam" texture, at a scale of 1 mm and 55X magnification, taken from apex section.


# Traditional Polyurethane Foam Imprint Texture (Secondary Manufacturing Process)

- This surface exhibits uneven nodules approximately 40 - 100 μm high and 50–150 μm in diameter, with high, flat-topped peaks and deep plunging crevasses" (Barr, Bayat and Hill, 2009).
- Silicon debris.
- Structures outside cellular dimensions.
- Potential Tissue Ingrowth.




SEM image of "negative imprint with foam" texture with some silicone debris on its nodular structure. (Barr, Bayat and Hill, 2009).


# Fibroblast Alignment Macro Surfaces






# Motiva Implants® Surfaces (Primary Manufacturing Process)





Motiva 3D Inversion™ Manufacturing Process.


# No additional treatments or process to manufacture Motiva Implants® SmoothSilk®/SilkSurface® or VelvetSurface®




Illustrative image by Establishment Labs

of the shell

# Motiva Implants® SmoothSilk®/SilkSurface®




SmoothSilk®/SilkSurface® 3D topography view taken with uSurf Mobile Profilometer per ISO 25178-2:2012




SmoothSilk®/SilkSurface® SEM image at a scale of 1 mm and 55X magnification

# High Density of Peaks




# Size comparison of a fibroblast on the surfaces











Representation of how a fibroblast may look on a breast implant surface at the same magnification, considering the standardized fibroblast size of 25 µm used by Dalby et al. (2004).


#### Fibroblast Alignment

A fibroblast is a cell in connective tissue which produces collagen and other fibres.


At a cellular level these fibroblasts adhere to very small substrates – They anchor to very small points.

Human fibroblasts are 20-25 microns in size and are affected by nano-topography

Cells prefer to adhere to very small substrates




# Fibroblast Alignment Nano Surfaces






# SilkSurface® has more peaks than valleys: Skewness Comparison



Skewness parameter comparison of different breast implants available in the market, measured with uSurf Mobile non-contact profilometer. Results Property of Establishment Labs (2017).



Roughness trace

# Motiva Nanotechnology Imprint<sup>TM</sup> is Designed to Reduce Damage to the Human Body Caused by Friction and Wear

SILKSURFACE<sup>TM</sup> IS DESIGNED TO REDUCE FRICTION AND INFLAMMATION



	Allergan Biocell	Mentor Siltex	Sientra True	SilkSurface®	Mentor Smooth
Roughness S <sub>a</sub>	80 <u>+</u> 12 μm	44 <u>+</u> 12 μm	34.4 <u>+</u> 8 μm	4 <u>+</u> 1 μm	0.022 <u>+</u> 0.0096 μm

Macro Textures Nano/Smooth

<sup>1.</sup> Motiva® Introduction to Motiva Implants: Safety Through Innovation. Las Vegas Slide Deck, 2016. 2. Derby BM, Codner MA. Textured Silicone Breast Implant Use in Primary Augmentation:

Core Data Update and Review. *Plast. Reconstr. Surg.* 2015;135(1): 113-124. 3. Data on file. Establishment Labs®. 4. Kyle DJT et al. *Biomaterials*. 52:88-102.

# BREAST IMPLANT SURFACE CATEGORIES

There have been different methodologies used to measure surface roughness and surface area. In 2018, the ISO (the International Organization for Standardization) test for surface characteristics was released and it classifies SmoothSilk®/SilkSurface® within the same category as traditional smooth implants.

#### SUMMARY OF SMOOTH & TEXTURED IMPLANT CLASSIFICATIONS<sup>1</sup>

ISO Average roughness by SEM		ANSM Average roughness by SEM		Atlan 2018 Surface area by X - ray and CT		Jones/Deva 2018 Surface area/roughness by SEM and CT		James/Kinney 2018 Surface area/roughness by profilometry	
Smooth <10 µm	All smooth,  Motiva Silk	Smooth	All smooth	Smooth/ nanotexture 80-100 mm <sup>2</sup>	All smooth, Motiva Silk and Velvet	<b>1</b> Minimal	All smooth,  Motiva Silk/Velvet	Smooth	All smooth,  Motiva Silk/Velvet
Microtextured 10 to 50 μm	Motiva Velvet, B-Lite, Allergan Microcell/BRST, Sientra True		Arion Micro, Sebbin Micro, Motiva Silk/Velvet	Microtextured 100-200 mm²	Mentor Siltex, Allergan Microcell /BRST	<b>2</b> Low	Mentor Siltex, Nagor		
Macrotextured over 50 μm	Allergan Biocell, Mentor Siltex, Silimed PU, Polytech PU	Macrotextured	Allergan Microcell/Biocell, Mentor Siltex, Eurosilicone Micro, Nagor, Polytech, Silimed	Macrotextured 200-300 mm <sup>2</sup>	Allergan Biocell, Sientra True, Eurosilicone	<b>3</b> Intermediate	Allergan Biocell, Eurosilicone	Rough	Allergan Biocell, Mentor Siltex
				Macrotexture-Plus > 300 mm²	Nagor, Polytech	<b>4</b> High	Polytech PU Surgitek PU Silimed PU		
Establishment Labs data generated  Data generated by ANSM per  ISO-14607:2007		Peer reviewed scientific publications							


Abbreviations: mm2: millimeters squared, SEM: scanning electron microscopy, ISO: the international Organization for Standardization., CT: Computed Tomography.

Surface area is a measure of the total area that the outer surface topography of an implant occupies and that interfaces with the patient. Surface roughness is a measure of the average height of the peaks and valleys of an implant surface.

### Roughness Comparison

#### **Breast Implant Classification Based on Surface Type**


International Organization for Standardization (ISO-14607:2018)



Establishment Labs data generated internally per ISO-14607:2018
Surface Characterization Report of different breast implants available in the market. TS-001019 Rev. 1, June 2019.


### SmoothSilk®/SilkSurface® Bio-Engineered Cell Friendly Surface

Three-dimensional (3D) surface imprinting for 360° controlled surface topography and optimal cellular response




### Complications associated with Biofilm Formation

Biofilm is a significant contributor to capsular contracture, potential trigger of ALCL




### Surface Area & Biofilm



Surface area measured for different breast implants and 24- hour average log(10) CFU/disc (Staphylococcus epidermidis bacteria attachment) to them, based on The Center of Biofilm Engineering Testing at Montana State University.

#### Less Bacterial Adhesion & Biofilm7.8

Surfaces with rougher texture and greater surface area promote a higher growth of bacteria compared to smoother surfaces.<sup>7,8</sup>




Confocal microscopy images of *S. epidermidis* and *P. aeruginosa* biofilms after 24 h of growth on breast implant surfaces. More biofilm was observed on the Biocell® and Siltex® textures than the SmoothSilk®/SilkSurface® and VelvetSurface® textures.

Independent testing performed by the Center for Biofilm Engineering, Montana State University, USA.

### SmoothSilk®/SilkSurface®

- Topography made of small dimensions
- More peaks than valleys
- High density of peaks
- Low inflammation
- Low roughness
- Low surface area
- Low bacteria attachment
- Less friction




SmoothSilk®/SilkSurface® 3D topography view taken with uSurf Mobile Profilometer


### Biocompatibility

Compatibility with living tissue or a living system by not being toxic, injurious or physiologically reactive and not causing immunological rejection

# Foreign Body Response



# Drivers that Increase the Risk of Capsular Contracture



### Prevention

- Less Biofilm
- Less Friction
- Less Silicon debris
- Less Gel Bleed
- Optimized surface topography

### Surface Optimization in Literature



Current Implant Surface Technology: An Examination of Their Nanostructure and Their Influence on Fibroblast Alignment and Biocompatibility

S. Barr, BSc, E. Hill, PhD, and A. Bayat PhD, MBBS, MRCSa

<sup>a</sup>Plastic & Reconstructive Surgery Research, Manchester Interdisciplinary Biocentre, The University of Manchester, Manchester, United Kingdom; and <sup>b</sup>Manchester Centre for Mesoscience & Nanotechnology, Information Technology Building, The University of Manchester, Manchester, United Kingdom

Correspondence: Ardeshir.Bayat@manchester.ac.uk

Published June 16, 2009

Biomaterials 52 (2015) 88-102

Contents lists available at ScienceDirect

#### Biomaterials

journal homepage: www.elsevier.com/locate/biomaterials

Development and functional evaluation of biomimetic silicone surfaces with hierarchical micro/nano-topographical features demonstrates favourable *in vitro* foreign body response of breast-derived fibroblasts

Daniel J.T. Kyle a, b, Antonios Oikonomou b, Ernie Hill b, Ardeshir Bayat a, \*



# Designing implant surface topography for improved biocompatibility

Expert Rev. Med. Devices 10(2), 257–267 (2013)

#### Alison G Harvey<sup>1</sup>, Ernie W Hill<sup>2</sup> and Ardeshir Bayat\*<sup>1,3</sup>

<sup>1</sup>Plastic and Reconstructive Surgery Research, Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK <sup>2</sup>The Manchester Centre for Mesoscience and Nanotechnology, The University of Manchester, Manchester, UK <sup>3</sup>Manchester Academic Health Science Centre, Institute of Inflammation Modern approaches to biomaterials aim to instigate a specific tissue response to create truly biocompatible materials. With this in mind, the responses of cells to biomimetic surface topographies have been studied. This review compares the findings and links the results to the processes which occur when cells contact a surface. Topographical features such as grooves and ridges or pits and pillars can have a dramatic effect on the composition of protein layers affecting protein orientation and conformation. It has been demonstrated that these surface properties along with others, such as surface compliance, can significantly impact on specific cell–surface interactions. Design strategies to minimize foreign body reactions should consider the shape, size, spacing and curvature of topographical features. In doing this, it should be possible to control the signals that are relayed to the nucleus and thus gain a degree of control over the cell behavior and ultimately the tissue response.

CrossMark

<sup>&</sup>lt;sup>a</sup> Plastic and Reconstructive Surgery Research, Manchester Institute of Biotechnology, University of Manchester, Manchester, UK

<sup>&</sup>lt;sup>b</sup> School of Computer Science, Centre for Mesoscience and Nanotechnology, The University of Manchester, Manchester, UK

Surface & Medical Complications
Linkage

Smooth Surface

• Higher Inflammation 1,2,3,4

• Higher Fibrosis 1,2,3,4

• Higher capsular contracture rates 1,2,3,4

• Lower Biofilm development 3,4

Macro Texture

- Associated with BI-ALCL <sup>6,9</sup>
- Capsular contracture rates still high. 1,2,3,4
- Higher Biofilm development 1,4,5,7,8 associated with capsular contracture 1,2,3,4
- Higher Double Capsule 16,17,18 and late Seroma rates 3,16,17

SilkSurface®

- Lower Inflammation 13,14
- Less Fibrosis <sup>13,14</sup>
- Less CC rates 10,11,12,13,14,19
- No ALCL reported cases 3,10,11,12
- Less Biofilm development 15

1.Barnsley, et al. 2006. 2. Stevens, et al., 2010. 3. FDA, 2011. 4. Jacombs, et al., 2014. 5. Hu, et al. 2014. 6. FDA, (BIA-ALCL), 2017. 7. Tamboto, Vickery & Deva, 2010. 8. Deva, Adams & Vickery, 2013. 9. Loch-Wilkinson, et al., 2107
10. Summary of Clinical Data 6-Year Follow-up. Establishment Labs. February 2016. 11. Preliminary Assessment of the Motiva Implants 3 years Follow-up report, 2016. 12. Dolan Park Hospital Report, 2016. 13. Barr, Hill, Bayat, 2009.
14. Doloff, J. C & Veiseh, 2017. 15. Garth-James, K. A. 2017. 16. Hall-Findlay, 2011. 17. Maxwell, et al. 2014. 18. Danino, 2015. 19. Motiva Implants® Post Market Surveillance Report (2017)


### SmoothSilk®/ SilkSurface®



# The Breezel Armasch of Matica Irralanta®

The Research Approach of Motiva Implants®

Research Fields:
Surface Characterization and Biocompatibility




#### Research External Collaboration Efforts








### Surface Area & Biofilm



Surface area measured for different breast implants and 24- hour average log (10) CFU/disc (Staphylococcus epidermidis bacteria attachment) to them, based on The Center of Biofilm Engineering Testing at Montana State University.

### Evaluation of the effect of SilkSurface® on fibrosis in vivo animal models




Research performed at the Robert Langer Laboratory at MIT, Boston, USA

# Gross examination of explanted Mini Control vs. SilkSurface® implant with tissue Traditional Smooth (Control) Overgrowth SmoothSilk®/SilkSurface®












Research performed at the Robert Langer Laboratory at MIT, Boston, USA

# Low Inflammatory Response Research

SmoothSilk® / SilkSurface® ameliorates fibrosis in B6 mice




Histological analysis of the tissue capsule surrounding the Smooth and SmoothSilk® / SilkSurface® tiny implants with two different staining techniques.

Research performed at the Robert Langer Laboratory at MIT, Boston, USA

# FACS analysis was used to quantify macrophages in tissue capsules surrounding implants





SilkSurface® decreases fibrosis-dependent innate immune macrophages.

# Full-size Human-scale Implants testing in Higher Order Rabbit Model 3-week retrievals


Traditional Smooth (control)







SmoothSilk®/
SilkSurface®








Research performed at the Robert Langer Laboratory at MIT, Boston, USA

# Controlled surface topography designed for fibroblast and macrophage attachment




SEM images of fibroblasts (obtained from breast tissue) and macrophages (from THP-1 monocytes cell line, ATCC) growing on different silicone surfaces.

SEM & 3D Representation images courtesy of Establishment Labs Fibroblast & macrophage images courtesy of Bayat A. University of Manchester

# 2 Optimal Immune System Response


#### Less Bacterial Adhesion & Biofilm<sup>7,8</sup>

Surfaces with rougher texture and greater surface area promote a higher growth of bacteria compared to smoother surfaces.<sup>7,8</sup>



Confocal microscopy images of *S. epidermidis* and *P. aeruginosa* biofilms after 24 h of growth on breast implant surfaces. More biofilm was observed on the Biocell® and Siltex® textures than the SmoothSilk®/SilkSurface® and VelvetSurface® textures.


# Low Inflammatory Response with Less Macrophages than Traditional Smooth<sup>9</sup>



SmoothSilk®/SilkSurface® decreases fibrosis-dependent innate immune macrophages in mouse capsule tissue.

## Less Fibrotic Encapsulation than Traditional Smooth<sup>9</sup>

SmoothSilk®/SilkSurface® ameliorates fibrosis in C57Bl6 mice




Asterisk shows where the implant was. Dotted red line delimits the capsule layers

Histological analysis of the tissue capsule surrounding traditional smooth implants on the left and SmoothSilk®/SilkSurface® tiny implants on the right with two different staining techniques.

# Tribology Testing

Tribology is the study of the surfaces moving relative to one another


- Wear particles
- Wear rate
- Friction coefficient



Tissue


# Tribology: Friction and Wear

- Static friction: is the force that must be overcome to start moving the object.
- Dynamic friction:
   relates to the force
   needed to keep a
   surface in motion at
   a constant velocity.



Comparative of static and dynamic average coefficients of different breast implants available in the market. Testing Performed on Akron Rubber Development Laboratory, Inc. Results Property of Establishment Labs (2017).

# 3D Topography views taken with uSurf Mobile Profilometer



This is an automatic zoom made by the equipment, note the color scale dimensions

# Conclusions from these Research Projects

- 1. Less biofilm formed on the SilkSurface® and VelvetSurface® than the "PU foam imprint" and "Salt-loss" macro-textures, showing a link between surface area and biolfilm load.
- 2. SmoothSilk®/SilkSurface® ameliorates the development of fibrotic capsules in mice and rabbit models compared to traditional smooth, showing that a nano scale surface reduces the innate immune response, leading to less aggressive capsules.
- 3. SmoothSilk®/SilkSurface® have less inflammatory cellular presence than traditional smooth implants in mice and rabbit models, demonstrating the improved biocompatibility of this surface.

# The Science of Breast Tissue Management Motiva Implants Clinical Evidence

# 2017 progress report at 6 years of a 10 year prospective study with MRI

#### Safety

No reported rupture, capsular contracture, double capsule or late seromas. No implant replacement due to clinical reasons.

100% of MRI cohort showed no evidence of implant rupture or capsular contracture

\*MRI cohort 62% of the patients (N=20)

	Complication	MRI cohort results 6-years follow-up (N=20)	6-years follow-up results (N=35)
<1%	Capsular contracture III/IV	0%	0%
	Rupture after implantation	0%	0%
	Late seroma	0%	0%
	Double capsule	*N/A	0%
	ALCL	*N/A	0%


<sup>\*</sup>Not applicable

<1%

Low complication rates in comparison to those reported in published literature regarding silicone gel-filled breast implants.

# Retrospective Study: 3-year follow-up of 5,813 consecutive causes with Motiva Implants® and competitor experience at Dolan Park Hospital in the United Kingdom performed by 16 Consultant Plastic Surgeons


Lower Reoperation Rate at 3 years



<1%

Low complication rates in comparison to those reported in published literature regarding silicone gel-filled breast implants.





#### **Article Contents**

**Abstract** 

**METHODS** 

**RESULTS** 

DISCUSSION

CONCLUSIONS

**REFERENCES** 

# Preliminary 3-Year Evaluation of Experience With SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience With 5813 Consecutive Breast Augmentation Cases 3

Marcos Sforza, MD ™, Renato Zaccheddu, MD, MSc, Angelo Alleruzzo, MD, Adriano Seno, MD, Domenico Mileto, MD, Arnaldo Paganelli, MD, Hassan Sulaiman, MD, Michael Payne, MD, Lajos Maurovich-Horvat, PhD

Aesthetic Surgery Journal, sjx150, https://doi.org/10.1093/asj/sjx150

Published: 14 September 2017



#### **Abstract**

#### **Background**

Silicone breast implants have been in use for breast augmentation for more than 50 years, but technological innovation has been lacking in implant design until recently.

# Study Design

- A Single-Center Experience, The Hospital Group, UK
- 16 Plastic Surgeons
- 5813 consecutive breast augmentation and revision cases
- SilkSurface<sup>®</sup> and VelvetSurface<sup>®</sup>

# Published Paper Conclusions

- Excellent safety profile
- Very low rates of early complications
- No late-term complications
- No cases of device-related implant rupture
- No primary capsular contracture (Baker III/IV) cases
- No double capsules/No late seromas
- Very low re-operation rate
- 3 times more complications with VelvetSurface® than SilkSurface®

#### MOTIVA IMPLANTS® 3 YEARS RETROSPECTIVE ANALYSIS

Study published in Aesthetic Surgery Journal



100% OF ASSESSED **PATIENTS** Mean of post-surgical follow-up

interval: 23 months

2506 with Motiva Implants® SilkSurface® (Representing more than 5000 implants)



One Study Site: Dolan Park Hospital in UK



#### **SURGICAL TECHNIQUE**

97%

INFRAMAMMARY INCISION

79%

**DUAL PLANE** 



#### RESULTS

**OVERALL COMPLICATION RATE** WITH MOTIVA IMPLANTS® SILKSURFACE® Complications were: Early Seroma, Infection, Dehiscence

#### NO CASES OF:

CAPSULAR CONTRACTURE DUE TO DEVICE FAILURE


RUPTURE

RIPPLING

LATE **SEROMA** 

# Retrospective Study: 3-year follow-up of 5,813 consecutive causes with Motiva Implants® and competitor experience at Dolan Park Hospital in the United Kingdom performed by 16 Consultant Plastic Surgeons

Complications Rates at 3 years



\*Implant ruptures related to contact with metal instruments.

No reports of implant rupture due to device failure.

# Motiva Implants® Post Market Vigilance Report

In the first 7 years since the launch more than 300,000 Motiva Implants® have been placed with only 108 clinically related adverse events reported.

Complications Rates (N=386,284)

<1%


Complication	Number of cases	Risk rates %
Capsular contracture III/IV	56	<1%
Rupture after implantation*	13	<1%
Late seroma	0	0%
Double capsule	0	0%
ALCL	0	0%


<sup>\*</sup>No cases of implant rupture due to device failure.

Clinical related events 0.028%

# Post-Market Surveillance – Motiva Implants®


Positive outcomes indicated by thin capsules CAPSULES FROM RE-OPERATIONS FOR SIZE CHANGE








# Multiple Levels of Clinical Evidence Indicate Superior Safety



Motiva Implants® real world data suggests superior clinical results according to the level of evidence provided by each report.

### 3 Positive Clinical Outcomes



Overall complication rates of less than 1% reported through 8 years of Post-Market Surveillance of Motiva Implants<sup>®12</sup>



#### **Overall Complication Rate**

with Motiva Implants® SmoothSilk®/SilkSurface®10

3 year retrospective clinical data in 5,813 patients with 16 plastic surgeons at 1 study site<sup>10</sup>



#### Implant Related Events<sup>11</sup>

6 year report on prospective safety outcomes

No implant rupture, capsular contracture, double capsule or late seroma at 6 years following 35 patients in a 10 year follow-up study with MRI assessment<sup>11</sup>


#### **CHOOSE WITH CONFIDENCE**

	Complication Severity					
		Low	High			
Complication Incidence	Uncommon	Cell-friendly advanced smooth  Motiva® implants	<b>Macrotexture</b> (chronic inflammation-related complications)			
	Common	<b>Traditional smooth</b> (capsular contracture)				

Although chronic inflammation-related complications with textured devices may be less common, smooth implants may be selected to minimize the risk. Traditional smooth implants have a high incidence of capsular contracture, whereas Motiva Implants® show a low risk of both capsular contracture and BIA-ALCL. 10,11,12

# MOTIVA IMPLANTS® OFFER THE MOST COMPREHENSIVE SMOOTH\* PORTFOLIO

#### **IMPLANT FAMILY OPTIONS**



FIRST-OF-ITS-KIND SAFETY FEATURES



**Q Inside®** RFID technology



**BluSeal®** Barrier layer



TrueMonobloc®

Shell-gel-patch configuration

## SAFETY THROUGH INNOVATION



#### References

- 1. Clemens, MW. PRS (2019 in press).
- 2. ISO 14607:2018. Non-active surgical implants Mammary implants particular requirements. Geneva, Switzerland: International Organization for Standardization.
- 3. Barr S, Bayat A. Breast implant surface development: perspectives on development and manufacture. Aesthet Surg J 2011; 31(1):56-67. doi: 10.1177/1090820X10390921
- 4. Barr S, Hill EW, Bayat A. Current implant surface technology: an examination of their nanostructure and their influence on fibroblast alignment and biocompatibility. Eplasty. 2009 Jun 16;9:e22.
- 5. Establishment Labs, Data on File TS-18-029.R Motiva Implants® Surface Characterization, Oct 2018.
- 6. Barr S, Hill EW, Bayat A. Functional biocompatibility testing of silicone breast implants and a novel classification system based on surface roughness. Journal of the Mechanical Behavior of Biomedical Materials. Nov 2017; 75:75-81. doi: 10.1016/j.jmbbm.2017.06.0306.
- 7. James G, Boegli L, Hancock J et al. Bacterial adhesion and biofilm formation on textured breast implant shell materials. Aesth Plast Surg. Oct 2018. doi: 10.1007/s00266-018-1234-7
- 8. Jones P, Mempin M, Hu H, et al. The functional influence of breast implant outer shell morphology on bacterial attachment and growth. Plast Reconstr Surg. 2018;142(4):837-849. doi: 10.1097/PRS.0000000000004801
- 9. Doloff J. Overcoming host rejection response to improve breast implant biocompatibility.15 Sep 2017. 3rd World Symposium on Ergonomic Implants, Lago di Garda.
- 10. Sforza M, Zaccheddu R, Alleruzzo A, et al. Preliminary 3-year evaluation of experience with SilkSurface and VelvetSurface Motiva silicone breast implants: a single-center experience with 5813 consecutive breast augmentation cases. Aesthet Surg J. 2018;38(Suppl 2):S62-S73. doi: 10.1093/asj/sjx150
- 11. Chacón M, Chacón M & Fassero J. Six-Year prospective outcomes of primary breast augmentation with nano-surface Implants. Aesthet Surg J. Nov 2018. doi: 10.1093/asj/sjy196
- 12. Establishment Labs Post-Market Surveillance Report Q3-2018

motiva.health 20190213 | SCM-1